This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
This document contains forward looking statements that can be identified by words like “hope,” “plan,”
“expect,” “believe,” “seek,” “estimate” and similar words. The information in this presentation
regarding forward looking statements of the Company, including business prospects, and operating,
financial, and growth projections are only predictions based on management expectations regarding
future performance. These estimates are highly dependent on the performance of the Brazilian
economy, industry and international market conditions. Therefore, they are subject to change.
3/18 Grupo
HIGHLIGHTS AND RECENT FACTS
GROWTH
GROSS REVENUE reached R$ 800.7 million in 3Q14 (+11.7%)
STRONG growth in OUTPATIENT (+14.5%) and LAB TO LAB (+14.9%)
2 LESS BUSINESS DAYS (3.0%) than 3Q13, which 2 were Brazil national team game
13 PSCs REMODELING delivered in 3Q14, 38 in progress and 6 new units
QUALITY
The implementation of a HOSPITAL LAB in the new Hospital das Américas, which will be one of Rio de Janeiro’s most important hospitals and was inaugurated in October
Global launch of Roche`s NEW CONVEYOR BELT at the Central Lab in the Federal District, with capacity expansion and possibility of decentralization
DELBONI INTERNATIONAL SYMPOSIUM had 1000 participants
30 DOCTORS from the Dasa group gave lectures during the Brazilian Congress of Radiology in Rio de Janeiro
RETURN FOR THE SHAREHOLDER
EBITDA of R$128.6 million in 3Q14, 6.5% more than 3Q13, reaching a margin of 17.7%
OPERATING CASH FLOW of R$113.0 million in 3Q14
NET INCOME of R$43.6 million in 3Q14
4/18 Grupo
GROSS REVENUE (R$ MILLION)
Gross revenue reached R$ 800.7 MILLION in 3Q14, a growth of 11.7%
520.9 596.6
69.2
73.176.5
87.950.2
43.2
3Q143Q13
Outpatient Inpatient Lab to Lab Public Sector
7.0%
10.7%
11.7%
14.9%
14.5%
74.5%
11.0%716.7
72.7%
5.4%-14.0%
800.7
9.1%
9.7%5.7%
475.9 528.6
240.9
272.1
3Q13 3Q14
RID Clinical Analysis
716.7
800.7
11.1%
13.0%
11.7%
66.4%
33.6%
34.0%
66.0%
5/18 Grupo
GROSS REVENUE | PATIENT SERVICE CENTERS
Strong RID growth
Mix of HIGHER COMPLEXITY (RID) EXAMS AND A HIGHER NUMBER OF EXAMS PER
REQUISITION increase the average requisition price
GROSS REVENUES (R$ MILLION) AVERAGE REVENUE PER REQUISITION (R$) AND
VOLUME (MILLIONS)
305.1 347.6
215.8
249.0
3Q13 3Q14Clinical Analysis RID
58.6%
41.4%
520.9
596.6
41.7%
58.3%
15.4%
14.5%
13.9%
3.5 3.8 3.8 3.5 3.6 3.6 3.9
134.0 133.7 138.9
146.3 148.6152.2 153.9
1Q13 2Q13 3Q13 4Q13 1Q14 2Q14 3Q14
Requisitions Average Requisition Price
6/18 Grupo
GROSS REVENUE | HOSPITALS
GROSS REVENUES (R$ MILLION) AVERAGE REVENUE PER REQUISITION (R$) AND
VOLUME (MILLIONS)
REQUISITIONS AVERAGE REQUISITIONS PRICE
GROWTH of 5.7%, operating with selectivity of clients
Increase in average ticket with implementation of NEW SERVICES and focus on INCREASING
PROFITABILITY
1.1 1.1 1.0 1.0 1.0 1.1 1.0
56.3 64.7
68.9 68.5 68.6 67.7 69.8
1Q13 2Q13 3Q13 4Q13 1Q14 2Q14 3Q14
Requisitions Average Requisition Price
52.4 57.2
16.815.9
3Q13 3Q14
Clinical Analysis RID
75.8%
24.2%
69.2 73.1
21.7%
78.3%9.2%
5.7%
-5.3%
7/18 Grupo
5,033 5,024
15.2
17.5
3Q13 3Q14
# of Laboratories Average Revenue/Laboratory (in Th R$)
GROSS REVENUE | LAB-TO-LAB
GROSS REVENUES (R$ MILLION) PERFORMANCE
15.1% increase in REVENUE per laboratory
Focus on GREATER CAPILLARITY and IMPROVING THE MIX OF EXAMS
76.5
87.9
3Q13 3Q14
14.9%
8/18 Grupo
GROSS REVENUE | PUBLIC HOSPITALS AND CLINICS
Contracts EXPIRATION
Selectivity in the CHOICE OF NEW CUSTOMERS
GROSS REVENUES (R$ MILLION) PERFORMANCE
50.2
43.2
3Q13 3Q14
-14.0%
591 591
84.9 73.1
3Q13 3Q14
# collecting site Revenue per collecting sites
9/18 Grupo
COSTS
PERSONNEL: impacted by collective bargaining agreement and hiring of new employees
MATERIAL: strong growth of lab-to-lab and image, and less growth of Clinical Analysis
SERVICES AND UTILITIES: doctor fee and expenses from representatives